Epsilogen

Epsilogen is a UK-based, clinical-stage biotech positioned as the world's leading pan-isotype antibody therapeutic company for cancer. Its core innovation is developing therapeutics based on IgE and IgA antibodies, which offer distinct mechanisms of action compared to conventional IgG antibodies, including enhanced tumor access and activation of different immune effector cells. The company's lead asset, MOv18 IgE, is in a Phase Ib trial for platinum-resistant ovarian cancer, and it bolstered its IgA platform through the 2025 acquisition of TigaTx. Epsilogen represents a novel approach in the immuno-oncology landscape by expanding the antibody arsenal beyond IgG.

Proprietary platforms for the discovery and development of therapeutic antibodies based on non-IgG isotypes, specifically Immunoglobulin E (IgE) and Immunoglobulin A (IgA). The platforms leverage the distinct effector functions of these isotypes, such as IgE's high-affinity tissue retention and activation of myeloid/T-cells, and IgA's potent engagement of neutrophils. The company also researches bispecific antibodies combining different isotypes.

Epsilogen is a first-in-class pioneer with no direct competitors developing clinical-stage therapeutic IgE antibodies for oncology. In the broader IgA space, it faces limited but emerging competition from other biotechs. Its primary competition is the entrenched paradigm of IgG-based therapeutics; it must demonstrate superior efficacy or activity in patient populations unmet by existing IgG drugs to gain market traction.